Role of ghrelin in fertilization, early embryo development, and implantation periods.

In order to clarify the physiological role of ghrelin in gestation, we evaluated the effects of administration of exogenous ghrelin (2 or 4 nmol/animal per day) or its antagonist (6 nmol/animal per day of (d-Lys3)GHRP6) on fertilization, early embryo development, and implantation periods in mice. Three experiments were performed, treating female mice with ghrelin or its antagonist: i) starting from 1 week before copulation to 12 h after copulation, mice were killed at day 18 of gestation; ii) since ovulation induction until 80 h later, when we retrieved the embryos from oviducts/uterus, and iii) starting from days 3 to 7 of gestation (peri-implantation), mice were killed at day 18. In experiments 1 and 3, the antagonist and/or the highest dose of ghrelin significantly increased the percentage of atrophied fetuses and that of females exhibiting this finding or a higher amount of corpora lutea compared with fetuses (nCL/nF) (experiment 3: higher nCL/nF-atrophied fetuses: ghrelin 4, 71.4-71.4% and antagonist, 75.0-62.5% vs ghrelin 2, 46.2-15.4% and control, 10-0.0%; n=7-13 females/group; P<0.01). In experiment 2, the antagonist diminished the fertilization rate, and both, ghrelin and the antagonist, delayed embryo development (blastocysts: ghrelin 2, 62.5%; ghrelin 4, 50.6%; and antagonist, 61.0% vs control 78.4%; n=82-102 embryos/treatment; P<0.0001). In experiment 3, additionally, ghrelin (4 nmol/day) and the antagonist significantly diminished the weight gain of fetuses and dams during pregnancy. Our results indicate that not only hyperghrelinemia but also the inhibition of the endogenous ghrelin effects exerts negative effects on the fertilization, implantation, and embryo/fetal development periods, supporting the hypothesis that ghrelin (in 'adequate' concentrations) has a physiological role in early gestational events.

Effects of PDC-109 on bovine sperm functional activity in presence or absence of heparin.

PDC-109, a heparin-binding protein (from the seminal vesicles) that binds to sperm surface phospholipids at ejaculation, may modulate several aspects of sperm activity. The objectives of the present study were to determine: (1) in the presence or absence of heparin, the effects of exogenous PDC-109 on sperm motility (Makler chamber), viability (Hoechst 33258) and membrane functional integrity (hypoosmotic swelling test) of bovine spermatozoa; (2) the role of PDC-109 as a capacitation-inducing factor; and (3) its ability to induce the acrosome reaction (fluorescein staining). After 4-h capacitation in the presence of heparin, the addition of PDC-109 (0.5, 1.5 or 3.0mg/ml) significantly decreased the percentages of motile, progressive, and viable cells; these effects were also detected in the absence of heparin. However, PDC-109 elicited a twofold increase (from 14 to 28%) in the proportion of acrosome-reacted spermatozoa, but only in the presence of heparin. Progesterone (10 microM) or angiotensin II (100 or 1000 nM) stimulated the acrosome reaction after capacitation in the presence of PDC-109 without heparin (from 10 to 17, 23 and 22%, respectively). In conclusion, PDC-109 appears to modulate sperm functional activity, with some effects manifest in the absence of heparin.